OLIGONUCLEOTIDES & PEPTIDES WORLD ASIA CONGRESS 2026

Inside the Global TIDES & RNA Partnerships

IMAPAC
IMAGINE YOUR IMPACT

INDUSTRY EBOOK · 2026

Inside the Global TIDES & RNA Partnerships

Shaping the Future of Oligonucleotide, Peptide & mRNA Therapeutics

The global RNA therapeutics and TIDES industry is entering a defining phase of commercial acceleration. Following the success of mRNA vaccine platforms and the growing validation of oligonucleotide therapeutics, biopharmaceutical companies are rapidly expanding manufacturing capacity, forming strategic partnerships, and investing in next-generation delivery technologies.

In 2026, the market is no longer driven solely by innovation; it is now driven by scalability, strategic alliances, and commercialization readiness. From enzymatic RNA synthesis and lipid nanoparticle (LNP) technologies to integrated CDMO ecosystems and AI-enabled oligonucleotide design, the RNA sector is witnessing unprecedented growth.

This report explores the most important partnerships, growth companies, manufacturing expansions, and technology developments shaping the future of RNA therapeutics and the broader TIDES landscape.

PART 01

Major RNA Partnerships Reshaping the Industry

Eli Lilly Expands Peptide Innovation Through PepLib Collaboration

The partnership combines PepLib's proprietary peptide library screening platform with Lilly's global clinical development and commercialization capabilities. Under the agreement, PepLib will identify peptide candidates while Lilly will lead IND-enabling studies, clinical development, and commercialization activities.

WHY THIS MATTERS

- Validates growing pharmaceutical interest in peptide therapeutics
- Highlights increasing China–US biotech collaborations
- Demonstrates continued expansion of peptide drug discovery platforms
- Strengthens Lilly's pipeline beyond GLP-1 obesity therapeutics

INDUSTRY TREND

Large pharmaceutical companies are aggressively expanding into:

- peptide engineering
- precision-targeted biologics
- metabolic disease therapeutics
- AI-driven peptide discovery

Neuland Laboratories & LIR Life Sciences

Neuland Laboratories entered a development partnership with LIR Life Sciences to support transdermal GLP-1 peptide therapies for obesity treatment.

Neuland Strengthens Position in GLP-1 Peptide Manufacturing

The collaboration focuses on advancing cell-penetrating peptide (CPP) technologies and scalable peptide manufacturing capabilities for next-generation obesity therapies.

KEY FOCUS AREAS

- transdermal GLP-1 delivery
- obesity therapeutics
- pharmacokinetic optimization
- peptide CDMO expansion
- scalable peptide manufacturing

WHY THIS MATTERS

As GLP-1 demand continues exploding globally, CDMOs with peptide synthesis expertise are becoming critical strategic partners for biopharma innovators.

Eli Lilly Acquires Orna Therapeutics to Expand Circular RNA & In Vivo Cell Therapy Capabilities

In one of the most significant RNA-related transactions of 2026, Eli Lilly announced the acquisition of Orna Therapeutics in a deal valued at up to $2.4 billion. The acquisition highlights growing pharmaceutical interest in next-generation RNA engineering platforms, particularly circular RNA (circRNA) technologies and in vivo CAR-T therapeutics.

Orna Therapeutics has been recognized for its proprietary circular RNA platform combined with advanced lipid nanoparticle (LNP) delivery systems. Unlike traditional mRNA approaches, circular RNA technologies may offer improved stability, durability, and protein expression capabilities.

The acquisition provides Lilly with access to:

- circular RNA engineering technologies
- in vivo CAR-T therapeutic platforms
- advanced LNP delivery systems
- autoimmune disease-focused RNA therapeutics

WHY THIS MATTERS

The deal reflects a major shift within the RNA therapeutics industry, where pharmaceutical leaders are increasingly investing beyond conventional mRNA vaccines into programmable cell therapies and genetic medicine platforms.

INDUSTRY IMPACT

- Accelerates big pharma investment into RNA therapeutics
- Validates circular RNA as an emerging therapeutic modality
- Expands industry focus on in vivo cell engineering
- Strengthens demand for advanced RNA manufacturing technologies

STRATEGIC TREND

The acquisition demonstrates how large pharmaceutical companies are aggressively building RNA ecosystems through acquisitions, platform licensing, and manufacturing integration strategies.

CODEXIS®

Codexis Expands Enzymatic RNA Manufacturing Collaborations

Codexis continues to strengthen its position within the RNA therapeutics ecosystem through strategic collaborations focused on enzymatic RNA synthesis technologies. Traditional chemical synthesis methods for RNA manufacturing often face scalability and sustainability limitations. Codexis aims to solve these challenges by developing enzymatic manufacturing approaches capable of producing high-purity RNA molecules more efficiently.

The company has increasingly partnered with pharmaceutical developers and manufacturing organizations seeking next-generation production capabilities for mRNA vaccines, siRNA therapeutics, and gene-editing applications.

WHY THIS MATTERS

- Enzymatic synthesis may significantly reduce manufacturing complexity.
- Faster RNA production could accelerate clinical development timelines.
- Pharmaceutical companies are actively seeking scalable RNA manufacturing alternatives.

GROWTH SIGNALS

- Increased investment into biocatalyst engineering
- Expansion of RNA manufacturing collaborations
- Rising demand from mRNA and oligonucleotide developers

Acuitas Therapeutics Strengthens RNA Manufacturing Ecosystem

Acuitas Therapeutics has emerged as one of the most influential players in RNA delivery technology, particularly in lipid nanoparticle (LNP) systems. The company's acquisition and strategic investments into RNA manufacturing capabilities demonstrate a broader industry trend toward vertically integrated RNA platforms.

By strengthening its manufacturing ecosystem, Acuitas is positioning itself as more than a delivery technology provider. The company is building an integrated model that combines RNA formulation, delivery optimization, and manufacturing scalability.

STRATEGIC FOCUS AREAS

- Advanced LNP delivery systems
- Manufacturing integration
- mRNA therapeutic platform expansion
- Global partnership development

WHY THIS MATTERS

Delivery technologies remain one of the biggest bottlenecks in RNA therapeutics. Companies capable of integrating delivery systems with scalable manufacturing will likely dominate the next phase of RNA commercialization.

Wacker Biotech & RNAV8 Bio Partnership

The partnership between Wacker Biotech and RNAV8 Bio reflects the increasing importance of integrated development and manufacturing workflows within the RNA therapeutics market.

Rather than operating as isolated service providers, companies are now forming collaborative ecosystems that streamline development from early-stage research through commercial manufacturing.

The collaboration focuses on accelerating:

- mRNA process development
- GMP manufacturing readiness
- Supply chain optimization
- Technology transfer efficiency

INDUSTRY IMPACT

This partnership highlights how CDMOs are evolving into strategic innovation partners rather than traditional manufacturing vendors.

EMERGING TREND

Integrated RNA development partnerships are becoming essential for reducing:

- regulatory delays
- manufacturing bottlenecks
- technology transfer risks
- commercialization timelines

Suzhou Ribo Life Science & Madrigal Pharmaceuticals

The collaboration between Suzhou Ribo Life Science and Madrigal Pharmaceuticals represents growing global confidence in siRNA therapeutics and cross-border innovation partnerships.

The agreement focuses on advancing RNA interference technologies for metabolic and liver-related diseases, reflecting the expanding therapeutic reach of RNA medicines beyond rare diseases and vaccines.

KEY STRATEGIC AREAS

- siRNA therapeutic development
- Clinical pipeline expansion
- Liver-targeted delivery technologies
- Global licensing opportunities

WHY INVESTORS ARE WATCHING

The partnership demonstrates how RNA therapeutics are increasingly moving toward large commercial disease markets rather than niche indications alone.

MARKET IMPLICATIONS

- Asia-based RNA innovators are gaining global relevance
- Licensing activity within RNA therapeutics is accelerating
- Large pharmaceutical companies continue increasing RNA investments

PART 02

Fastest Growing RNA & TIDES Companies

Codexis

Codexis is rapidly becoming a major innovation leader within enzymatic RNA manufacturing. The company's expansion into RNA therapeutics aligns with growing industry demand for sustainable and scalable production technologies.

GROWTH DRIVERS

- Expansion into RNA manufacturing technologies
- Strategic pharmaceutical collaborations
- Increased focus on biocatalyst engineering
- Growing relevance in mRNA production

COMPETITIVE ADVANTAGE

Codexis combines enzyme engineering expertise with scalable manufacturing solutions, positioning the company as a critical technology provider for future RNA production.

OliX Pharmaceuticals

OliX Pharmaceuticals continues gaining attention for its RNA interference (RNAi) therapeutic pipeline targeting ophthalmology, fibrosis, and dermatology applications.

The company's growing clinical pipeline and international expansion efforts place it among the emerging innovators within the oligonucleotide therapeutics sector.

KEY GROWTH INDICATORS

- Expansion of RNAi therapeutic programs
- Clinical trial progression
- Increasing international partnerships
- Strengthening intellectual property portfolio

INDUSTRY POSITION

OliX represents the next generation of RNAi-focused biotech companies moving toward broader commercial relevance.

Acuitas Therapeutics

Acuitas Therapeutics remains one of the most strategically important companies within the RNA delivery landscape.

Its proprietary LNP technologies became globally recognized during the mRNA vaccine expansion period and continue supporting next-generation therapeutic applications.

STRATEGIC GROWTH AREAS

- Delivery platform licensing
- Manufacturing ecosystem expansion
- mRNA therapeutic partnerships
- Global collaboration network growth

WHY ACUITAS STANDS OUT

The future success of RNA therapeutics depends heavily on delivery optimization, making Acuitas one of the sector's most valuable technology enablers.

Atrium Therapeutics

Atrium Therapeutics is attracting industry attention through aggressive expansion strategies, pipeline development initiatives, and strategic manufacturing investments.

The company is increasingly positioning itself within advanced therapeutic modalities and precision medicine applications.

EXPANSION SIGNALS

- Research platform growth
- Increased clinical development activity
- Strategic partnerships
- Manufacturing capability investments

MARKET POTENTIAL

Companies combining innovation with scalable commercialization infrastructure are expected to outperform in the evolving RNA market.

Asymchem Builds Fully Integrated TIDES Manufacturing Hub

The company significantly expanded solid-phase peptide synthesis (SPPS) reactor capacity and integrated peptide and oligonucleotide manufacturing workflows to support rising global TIDES demand.

GROWTH SIGNALS

- Expanded SPPS reactor infrastructure
- Increased peptide API manufacturing capacity
- Integrated commercial TIDES supply chain
- Advanced purification and scale-up technologies

INDUSTRY IMPACT

The expansion reflects growing industry demand for:

- end-to-end TIDES manufacturing
- large-scale peptide production
- integrated CDMO ecosystems
- commercial readiness for advanced therapeutics

PART 03

Conclusion

The RNA therapeutics and TIDES industry is entering a transformative commercial era defined by strategic collaboration, manufacturing scalability, and delivery innovation.

Companies capable of integrating platform technologies, scalable manufacturing, and strong partnership ecosystems are expected to lead the next generation of RNA medicine development.

As investment, licensing activity, and global manufacturing capacity continue expanding, the RNA sector is positioned to become one of the most strategically important areas within modern biopharmaceutical innovation.

The coming years will likely determine which companies emerge as long-term leaders in the rapidly evolving RNA therapeutics landscape.

OLIGONUCLEOTIDES & PEPTIDES WORLD ASIA CONGRESS 2026

30 June - 31 July 2026,
Sands Expo & Convention Centre,
Singapore

MEET THE LEADERS DRIVING THE FUTURE OF TIDES & RNA THERAPEUTICS

Norihiko Shiraishi
Chief Scientific Officer,
NANO MRNA Co., Ltd., Japan

Janya Grainok
Chief Scientific Officer,
PYC Therapeutics, Australia

Dr. Ya-Shan Chuang
Director of Medical Affairs,
Immunwork, Taiwan

Adam Zhao
Chairman & CEO,
Anlong Bio Inc., China

Bo Ying
Founder, Chairman & CEO,
Abogen Biosciences, China

Madhavan Nallani
Founder & CEO,
ACM Biolabs, Singapore

Dr. Tomoya Takenaka
Principal Scientist, Drug Product and Device Development, Takeda Pharmaceutical Company, Japan

Mohamed ElSayed
Executive Director,
Nucleic Acid Therapeutics Initiative (NATi), Singapore

Prof. Rakesh Veedu
Professor, Murdoch University; Founder & CTO, SynGenis Pty Ltd; Co-Founder & MD/CEO, ProGenis Pharmaceuticals

Yasumasa Ota
mRNA technology Leader,
Meiji, Japan

Kim Seokjoong
CSO, BreezeBio

Volker Patzel
Assistant Professor,
National University of Singapore, Singapore

Xuezhi Bi
Senior Principal Scientist,
Group Leader (Protein Analytics),
Bioprocessing Technology Institute,
A*STAR, Singapore

Janise Chevrier-Lee
Country Medical Director Singapore,
Roche Singapore Pte Ltd to ebook.

Jia-Ming Chang
CEO, Vacino Biotech, Taiwan

Wonil Kim
CSO, Aston Sci.

Poon Hung Fai
CEO, Sirnaomics

Xian Zeng
CEO & Founder,
Byterna Therapeutics

Jagadish Sankaran
Senior Scientist,
A*STAR, Singapore

Jin Li
Head of Research Department,
CanSino (Shanghai) Biological Research Co., Ltd, China



Crystal Lau
Senior Director CMC,
MSD, Singapore

Arvind K Jain
Deputy General Manager,
R&D – mRNA Vaccines,
Biological E. Limited, India

➔ VISIT OUR WEBSITE AND REGISTER NOW